Among more than 5,000 patients followed for a median of roughly 8 years, bilateral risk-reducing mastectomy (RRM) was ...
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to ...
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral ...
AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term results ...
Patients with high-risk, BRCA-positive breast cancer who received olaparib after standard treatment continued to have better ...
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral ...
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing ...
The rates of late-stage breast cancer at diagnosis have risen among women in all racial and ethnic groups, but Black women ...
AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback